NEW YORK (GenomeWeb News) – Cellular Dynamics International today reported that its second quarter revenues increased 123 percent year over year, driven by sales of its iCell products.

The Madison, Wis.-based firm brought in total revenues of $2.8 million for the three months ended June 30, compared to $1.3 million for the second quarter of 2012. It said that the revenue growth was primarily attributable to growth in unit sales of its iCell human induced pluripotent stem cell-derived products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.